Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
AssigneeThe Board of Trustees of the University of Illinois
InventorsYulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
Life of this patent
Estimating the term…
Abstract
Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.
Claims13
A conjugated peptide comprising an amino acid sequence selected from the group consisting of KFARLWTEIPTAIT (SEQ ID NO:
- 1) and FTEIPTI (SEQ ID NO:
- 3), wherein the conjugated peptide is linked to a carrier peptide or myristoyl group.
A conjugated peptide consisting of the amino acid sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 3, linked to a carrier peptide or a myristoyl group.
Dependencies are inferred from the claim text.